Evidence map›Paper›PMID 39648952›Full record

ArticleHistopathology2025

Is it time to acknowledge intramucosal colorectal carcinoma?

Elisa Vink-Börger, Nikki Knijn, Adriaan de Bruine, Jeroen Stavast, Rachel Sophia van der Post, Iris Nagtegaal

Abstract read
In one paragraph

Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elisa Vink-BörgerDepartment of Pathology, Radboudumc, Nijmegen, The Netherlands.ORCID https://orcid.org/0009-0007-2230-8806
Nikki KnijnDNA-Pathology, Arnhem, The Netherlands.ORCID https://orcid.org/0000-0003-1876-7261
Adriaan de BruineDepartment of Pathology, Viecuri Hospital, Venlo, The Netherlands.
Jeroen StavastPathology South-West Netherlands, Tilburg, The Netherlands.
Rachel Sophia van der PostDepartment of Pathology, Radboudumc, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-7531-9599
Iris NagtegaalDepartment of Pathology, Radboudumc, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-0887-4127

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe term 'intramucosal carcinoma' in the colorectum is controversial when used as a synonym for high-grade dysplasia. However, setting clear definitions for this diagnosis (i.e. unequivocal infiltrative growth in the lamina propria, which might be most easily recognized in cases with overt poor differentiation or formation of signet ring cells or tumour budding) allow us to investigate its relevance. METHODS AND

resultsWe reviewed cases from our archive (1990-2024) and selected 14 true intramucosal carcinomas using our strict histological criteria, excluding high-grade dysplasia and invasive carcinomas. These occur primarily in conventional adenomas and are frequently associated with microsatellite instability (50%). Our study shows a low estimated incidence of intramucosal carcinoma (0.01%) in population screening and highlights the low lymph node risk and the good outcome of patients with intramucosal carcinoma.

conclusionThe rare diagnosis of intramucosal colorectal carcinoma aids in identifying patients at increased colorectal cancer risk, notably those with hereditary syndromes. Standardizing this diagnosis is critical to prevent overdiagnosis and unnecessary treatment.

Indexed as

AdenocarcinomaColorectal NeoplasmsAdenomaAdultAgedAged, 80 and overFemaleHumansIntestinal MucosaMaleMicrosatellite InstabilityMiddle Agedcolorectal cancerintramucosal carcinomamismatch repair deficiency

Identifiers

PMID39648952
PMCPMC11903115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.